- Home
- ATRA vs CCEL Comparison
ATRA vs CCEL Comparison
Compare ATRA & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATRA
- CCEL
- Stock Information
- Founded
- ATRA 2012
- CCEL 1989
- Country
- ATRA United States
- CCEL United States
- Employees
- ATRA N/A
- CCEL N/A
- Industry
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- CCEL Managed Health Care
- Sector
- ATRA Health Care
- CCEL Health Care
- Exchange
- ATRA Nasdaq
- CCEL Nasdaq
- Market Cap
- ATRA 40.1M
- CCEL 39.9M
- IPO Year
- ATRA 2014
- CCEL 1997
- Fundamental
- Price
- ATRA $7.94
- CCEL $5.13
- Analyst Decision
- ATRA Buy
- CCEL Strong Buy
- Analyst Count
- ATRA 5
- CCEL 1
- Target Price
- ATRA $17.75
- CCEL $8.50
- AVG Volume (30 Days)
- ATRA 61.5K
- CCEL 8.3K
- Earning Date
- ATRA 08-11-2025
- CCEL 07-14-2025
- Dividend Yield
- ATRA N/A
- CCEL 7.80%
- EPS Growth
- ATRA N/A
- CCEL N/A
- EPS
- ATRA N/A
- CCEL 0.01
- Revenue
- ATRA $199,732,000.00
- CCEL $32,102,750.00
- Revenue This Year
- ATRA N/A
- CCEL $2.49
- Revenue Next Year
- ATRA N/A
- CCEL $0.95
- P/E Ratio
- ATRA N/A
- CCEL $322.13
- Revenue Growth
- ATRA 475.53
- CCEL 2.33
- 52 Week Low
- ATRA $5.01
- CCEL $4.75
- 52 Week High
- ATRA $18.71
- CCEL $9.43
- Technical
- Relative Strength Index (RSI)
- ATRA 48.77
- CCEL 50.16
- Support Level
- ATRA $7.74
- CCEL $5.00
- Resistance Level
- ATRA $9.00
- CCEL $5.31
- Average True Range (ATR)
- ATRA 0.54
- CCEL 0.22
- MACD
- ATRA -0.12
- CCEL 0.02
- Stochastic Oscillator
- ATRA 19.79
- CCEL 43.09
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.